Revusiran ( DrugBank: Revusiran )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
28全身性アミロイドーシス5

28. 全身性アミロイドーシス


臨床試験数 : 267 薬物数 : 241 - (DrugBank : 77) / 標的遺伝子数 : 68 - 標的パスウェイ数 : 180
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2015-005333-49-GB
(EUCTR)
30/06/201604/04/2016A study to look at the long-term efficacy and safety of ALN-TTRSC in patients with an inherited condition that causes certain protein molecules to deposit in the heartA Multicenter, Multinational, Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of Revusiran in Patients with Transthyretin-mediated Familial Amyloidotic Cardiomyopathy Transthyretin (TTR) mediated familial amyloidotic cardiomyopathy (FAC)
MedDRA version: 18.1;Level: PT;Classification code 10016202;Term: Familial amyloidosis;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: Revusiran
Product Code: ALN-TTRSC
INN or Proposed INN: Revusiran
Other descriptive name: ALN-51547
Alnylam Pharmaceuticals, Inc.NULLNot RecruitingFemale: yes
Male: yes
200Phase 3United States;France;Mexico;Canada;Spain;Brazil;Belgium;Germany;Italy;United Kingdom;Sweden
2EUCTR2014-003835-20-DE
(EUCTR)
24/06/201502/12/2014A study to look at the efficacy and safety of ALN TTRSC in patients with an inherited condition that causes certain protein molecules to deposit in the heartA Phase 3 Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALN TTRSC in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC) Transthyretin (TTR) mediated familial amyloidotic cardiomyopathy (FAC)
MedDRA version: 19.0;Level: PT;Classification code 10016202;Term: Familial amyloidosis;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: ALN-TTRSC
Product Code: ALN-TTRSC
INN or Proposed INN: Revusiran
Other descriptive name: ALN-51547
Alnylam Pharmaceuticals, Inc.NULLNot RecruitingFemale: yes
Male: yes
200Phase 3France;United States;Mexico;Canada;Brazil;Belgium;Spain;Germany;Italy;United Kingdom;Sweden
3EUCTR2014-003835-20-SE
(EUCTR)
20/05/201527/11/2014A study to look at the efficacy and safety of ALN TTRSC in patients with an inherited condition that causes certain protein molecules to deposit in the heartA Phase 3 Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALN TTRSC in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC) Transthyretin (TTR) mediated familial amyloidotic cardiomyopathy (FAC)
MedDRA version: 19.0;Level: PT;Classification code 10016202;Term: Familial amyloidosis;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: ALN-TTRSC
Product Code: ALN-TTRSC
INN or Proposed INN: Revusiran
Other descriptive name: ALN-51547
Alnylam Pharmaceuticals, Inc.NULLNot RecruitingFemale: yes
Male: yes
200Phase 3France;United States;Mexico;Canada;Brazil;Belgium;Spain;Germany;Italy;United Kingdom;Sweden
4EUCTR2014-003835-20-BE
(EUCTR)
25/03/201503/02/2015A study to look at the efficacy and safety of ALN TTRSC in patients with an inherited condition that causes certain protein molecules to deposit in the heartA Phase 3 Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALN TTRSC in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC) Transthyretin (TTR) mediated familial amyloidotic cardiomyopathy (FAC)
MedDRA version: 18.1;Level: PT;Classification code 10016202;Term: Familial amyloidosis;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: ALN-TTRSC
Product Code: ALN-TTRSC
INN or Proposed INN: Revusiran
Other descriptive name: ALN-51547
Alnylam Pharmaceuticals, Inc.NULLNot RecruitingFemale: yes
Male: yes
200Phase 3France;United States;Mexico;Canada;Brazil;Spain;Belgium;Germany;Italy;United Kingdom;Sweden
5EUCTR2014-003835-20-GB
(EUCTR)
26/11/201417/10/2014A study to look at the efficacy and safety of ALN TTRSC in patients with an inherited condition that causes certain protein molecules to deposit in the heart.A Phase 3 Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALN TTRSC in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC) Transthyretin (TTR) mediated familial amyloidotic cardiomyopathy (FAC)
MedDRA version: 18.1;Level: PT;Classification code 10016202;Term: Familial amyloidosis;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: ALN-TTRSC
Product Code: ALN-TTRSC
INN or Proposed INN: Revusiran
Other descriptive name: ALN-51547
Alnylam Pharmaceuticals, Inc.NULLNot RecruitingFemale: yes
Male: yes
200Phase 3Brazil;Belgium;Spain;Germany;Italy;France;United States;Canada;United Kingdom;Sweden